Moran Timothy P. 4

What Happened
Timothy P. Moran, Chief Business Officer of Kestra Medical Technologies, received an award of 22,704 restricted stock units (RSUs) on June 3, 2026. The reported acquisition price is $0 (an equity award/grant rather than a market purchase or sale). These RSUs will convert to one share each upon settlement subject to the vesting schedule.

Key Details

• Transaction date: 2026-06-03; filing date: 2026-06-04 (timely filing).
• Transaction type/code: Award/Grant (Form 4 code "A").
• Amount: 22,704 RSUs; reported acquisition price: $0; total reported value $0 at grant.
• Shares owned after the transaction: not specified in the provided filing.
• Footnote: RSUs vest over three years with 1/3 vesting on each anniversary of June 3, 2026, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported.

Context
RSUs are compensation awards that convert to common shares when they vest/settle; they are not an open-market purchase or sale and do not necessarily signal immediate trading intent. Taxes are typically due when RSUs vest or settle, and the award vests over time contingent on continued employment.